STADA and Bio-Thera Launch Gotenfia®, a New Biosimilar to Simponi in Europe STADA and Bio-Thera have gained European authorization for Gotenfia®, a biosimilar of Simponi. This innovative treatment targets autoimmune diseases and enhances patient access across Europe.

STADA and Bio-Thera Launch Gotenfia®, a New Biosimilar to Simponi in Europe #Germany #Bio-Thera #STADA #Gotenfia #Bad_Vilbel

STADA and Bio-Thera Celebrate EMA's Positive Opinion for Gotenfia, a Golimumab Biosimilar STADA and Bio-Thera's golimumab biosimilar, Gotenfia, has received a positive opinion from the EMA, paving the way for its approval in the EU and several other countries.

STADA and Bio-Thera Celebrate EMA's Positive Opinion for Gotenfia, a Golimumab Biosimilar #Germany #Bio-Thera #STADA #Gotenfia #Bad_Vilbel